Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42312   clinical trials with a EudraCT protocol, of which   6968   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2007-004646-33
    Sponsor's Protocol Code Number:DORINOS3008
    National Competent Authority:Hungary - National Institute of Pharmacy
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2008-01-10
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedHungary - National Institute of Pharmacy
    A.2EudraCT number2007-004646-33
    A.3Full title of the trial
    A Prospective, Randomized, Double-Blind, Double-Dummy, Multicenter Study to Assess the Safety and Efficacy of Doripenem Compared With Imipenem-Cilastatin in the Treatment of Subjects with Ventilator-Associated Pneumonia
    A.4.1Sponsor's protocol code numberDORINOS3008
    A.7Trial is part of a Paediatric Investigation Plan Information not present in EudraCT
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorJanssen-Cilag International NV
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Doribax
    D.2.1.1.2Name of the Marketing Authorisation holderJanssen-Cilag International N.V.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDoripenem
    D.3.2Product code JNJ-38174942
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDoripenem monohydrate
    D.3.9.1CAS number 364622-82-2
    D.3.9.2Current sponsor codeJNJ-38174942
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name ZINEAM® 500mg powder for solution for infusion
    D.2.1.1.2Name of the Marketing Authorisation holderMDS SHARP & DOHME GBMH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Powder for solution for infusion
    D.3.4.1Specific paediatric formulation Information not present in EudraCT
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNImipenem
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCilastatin
    D.3.9.1CAS number 82009-34-5
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) Information not present in EudraCT
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Information not present in EudraCT
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Information not present in EudraCT
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for infusion
    D.8.4Route of administration of the placeboIntravenous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Ventilator-Associated Pneumonia
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 9.1
    E.1.2Level LLT
    E.1.2Classification code 10065153
    E.1.2Term <Manually entered code. Term in E.1.1>
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective is to demonstrate the noninferiority of a 7-day course
    of doripenem to a 10-day course of imipenem-cilastatin with respect to the clinical
    cure rate at the EOT visit in clinically evaluable subjects with VAP.
    E.2.2Secondary objectives of the trial
    Demonstrate:
    ·noninferiority of doripenem to imipenem-cilastatin with respect to the clinical cure rate at the EOT in ME subjects.
    ·superiority of doripenem relative to imipenem-cilastatin with regard to clinical cure rate at EOT in ME subjects from whom P. aeruginosa are isolated from LRT specimen at baseline, or at least one of the following specific serious gram negative organisms is isolated at baseline: any Enterobacteriaceae, P. aeruginosa, and Acinetobacter spp.
    ·that for P. aeruginosa, emergent resistance is lower in doripenem subjects.

    ·Compare other clinical/microbiologic responses between the 2 groups.
    ·Explore correlation of diagnostic and early markers of efficacy with clinical outcome, relationship between the imipenem-cilastatin concentration/MIC with clinical outcome & exposure-response relationships for doripenem microbiologic and clinical outcomes using PK/PD modeling.
    ·Evaluate medical resource utilization, safety of 1-g dose of doripenem.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    ·Men or women 18 years of age or older
    ·Have new or progressive radiographic infiltrates consistent with VAP that is not related to cardiac or other disease processes. Chest X-rays obtained within 36 hours before the first dose of study drug are acceptable for the screening examination. A CT scan may be used in place of a chest X-ray if the chest X-ray is not sufficiently interpretable.
    ·Have at least 1 of the following:
    –Fever (in the absence of antipyretics): a rectal temperature greater than 39°C OR an increase in core temperature of greater than 1°C above normal
    –Hypothermia, defined as a rectal/core body temperature of less than 35°C
    –Leukocytosis (WBC count >10x109/L or >15% immature neutrophils, regardless of the total peripheral white cell count; or leukopenia with total WBC count less than 4x109/L
    ·Have been mechanically ventilated for >48 hours and on mechanical ventilation at the time of randomization. (Subjects who failed prior antibiotic treatment for the current VAP may be considered if: a) they received the prior antibiotic for >48 hours; b) they have been ventilated for at least 72 hours; c) they have persistent signs and symptoms of VAP; d) they have a repeat BAL performed before first dose of study drug. Subjects enrolled as failures of prior therapy must meet t, both of the following criteria to continue on study drug:
    ·The isolate(s) from the quantitative culture of the BAL must be >10*4 CFU/mL
    ·At least 1 pathogen that grows from the quantitative culture of the BAL
    specimen at ≥10*4CFU/mL must be susceptible to imipenem-cilastatin and
    resistant to the prior failed antibiotic therapy(ies) administered for the
    current episode of VAP.
    At least 1 qualifying pathogen (i.e. ≥10*4 CFU/mL and imipenem MIC
    ≤8μg/mL) from the quantitative culture of the baseline BAL is required for a
    subject to continue on study drug irrespective of whether he/she was enrolled
    as a prior failure or not.
    ·Have been hospitalized for a minimum of 5 consecutive days before signing the informed consent form (residents of chronic health care facilities do not have to fulfill this 5-day requirement. Residency in a chronic health care facility is defined as having spent any 5 days in the facility in the past 90 days)
    ·Have a baseline CPIS of >6
    ·Have an APACHE II Score of >8 and <35
    ·Have a bronchoscopic BAL/mini-BAL plus tracheal aspirate performed at baseline. (A bronchoscopic BAL/mini-BAL may be performed up to 36 hours before the first dose of study drug.
    ·Women must be postmenopausal (for at least 1 year), surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy), abstinent (at the discretion of the investigator), or, if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], male partner sterilization) before entry and must agree to continue to use the same method of contraception throughout the study; have a negative serum beta-human chorionic gonadotropin (b hCG] or urine pregnancy test at screening (depending on local regulations)
    ·Willing to adhere to the prohibitions and restrictions specified in this protocol
    ·Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. Consent may be given for unconscious/incapacitated subjects by a legally authorized representative, according to local regulatory and ethical practice using a subject information sheet and informed consent form approved by the responsible Ethics Committee. When a subject is no longer incapacitated, informed consent will be obtained from the subject at that time.
    E.4Principal exclusion criteria
    ·Received >24 hours of prior antibiotics (before the first dose of study drug) for the current episode of VAP. Note: Subjects will not be excluded if all of the following criteria are met:
    –this prior antibiotic therapy has been given for >48 hours
    –the subject is failing on the prior antibiotic as shown by clinical assessments
    –the failing antibiotic has not been changed in the 24-hour period between signing the informed consent form and the administration of the first dose of study drug.
    ·Known presence at baseline of only MRS or Stenotrophomonas infection from the quantitative culture of the baseline BAL
    ·Have acute respiratory distress syndrome (ARDS defined by diffuse radiographic infiltrates and PaO2 to FiO2 ratio <200)
    ·Has any of the following conditions that interfere with the assessment or interpretation of the diagnosis or response to therapy:
    –Chest trauma with severe lung contusion or flail chest. (A CT scan is recommended in subjects with a history of traumatic chest injury when pneumonia cannot be clearly distinguished from severe lung contusion on the chest X-ray).
    –Pleural effusion(s) requiring drainage or empyema
    –Active lung cancer-primary or secondary within the last 2 years
    –Chronic bronchitis with an exacerbation within the last 30 days
    –Bronchiectasis
    –Lung abscess(s)
    –Anatomical bronchial obstruction
    –Respiratory tuberculosis on treatment
    –Suspected atypical pneumonia
    –Chemical pneumonitis (e.g., aspiration of gastric contents, inhalation injury)
    –Cystic fibrosis
    –Congestive Heart Failure as noted by the New York Heart Association Classification IV
    –Active seizure disorder within the last 2 years or brain injury such that imipenem-cilastatin would not be administered to the subject in usual practice
    –Severe full thickness burns to greater than 15% of the body
    –Cirrhotic liver disease.
    ·Severe impairment of renal function defined as a CLCR <10 mL/min requiring either continuous renal replacement therapy (CRRT), peritoneal dialysis, hemodialysis, hemofiltration, OR oliguria, defined as a urine output <20 mL of urine/hour over 24 hours
    ·History of active immunosuppression, including: acquired immunodeficiency syndrome (AIDS), organ (including bone marrow) transplant recipients who have received immunosuppressive therapy within the past 60 days, active hematologic malignancy, OR chronic use of high-dose corticosteroids, defined as >40 mg/d of systemic prednisone (or equivalent per day) for more than2 weeks during the current admission. (Subjects with a history of non-chronic rapid tapering of steroid therapy will be considered for enrollment.)
    ·History of any rapidly progressing disease or immediately life-threatening illness (defined as imminent death within 24 hours) that in the opinion of the investigator makes the subject very unlikely to survive the 5-to -6 week study period
    ·History of hypersensitivity reactions to carbapenems, penicillins, other b lactam antibiotics, or b lactamase inhibitors (subjects with a history of mild skin rash, documented not to have been caused by previous b lactam use are permitted to enroll)
    ·Have previously received doripenem, meropenem, or imipenem-cilastatin in the last week
    ·Have any other known or suspected condition that may jeopardize adherence to protocol requirements or interpretation of adverse events
    ·Suspicion of pulmonary edema as a cause of the acute illness
    ·Hematocrit of less than 22% or hemoglobin of less than 7 g/dL
    ·Neutropenia with absolute neutrophil count of less than 1,000 cell/mm3. Subjects with neutrophil counts as low as 500 cells/mm3 are permitted if the reduction is due to the acute infection process.
    ·Platelet count of less than 50,000 cells/mm3
    ·Current use of probenecid or valproic acid
    ·Are hospitalized involuntarily (e.g., vulnerable populations like prisoners or the mentally impaired)
    ·Have received an experimental medication or used an experimental therapeutic medical device within 30 days. Subjects in clinical studies for approved products will not be excluded.
    ·Is breast-feeding
    ·Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
    E.5 End points
    E.5.1Primary end point(s)
    Primary efficacy endpoint
    ·Clinical cure rate at the EOT visit in clinically evaluable subjects.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence Information not present in EudraCT
    E.6.9Dose response Information not present in EudraCT
    E.6.10Pharmacogenetic Information not present in EudraCT
    E.6.11Pharmacogenomic Information not present in EudraCT
    E.6.12Pharmacoeconomic Information not present in EudraCT
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Microbiologic Efficacy Assessments
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Information not present in EudraCT
    E.7.1.1First administration to humans Information not present in EudraCT
    E.7.1.2Bioequivalence study Information not present in EudraCT
    E.7.1.3Other Information not present in EudraCT
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Information not present in EudraCT
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) Information not present in EudraCT
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned Information not present in EudraCT
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA30
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months1
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months1
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.3Elderly (>=65 years) Yes
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers Information not present in EudraCT
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 180
    F.4.2.2In the whole clinical trial 524
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2008-07-08
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2008-06-25
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA